Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immutep Ltd ( (AU:IMM) ) has shared an update.
Immutep Ltd has announced the quotation of 33,904 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of July 18, 2025. This move is part of the company’s ongoing efforts to enhance its financial flexibility and strengthen its market position, potentially benefiting its stakeholders by increasing liquidity and visibility in the market.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments. The company is primarily engaged in creating therapies that modulate the immune system for cancer and autoimmune diseases.
Average Trading Volume: 3,221,289
Technical Sentiment Signal: Sell
Current Market Cap: A$350.5M
For an in-depth examination of IMM stock, go to TipRanks’ Overview page.